Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT00076089 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

Start date: December 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

NCT ID: NCT00069823 Completed - Asthma Clinical Trials

Study of Acid Reflux in Asthma

Start date: September 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.

NCT ID: NCT00064415 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

Start date: June 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD

NCT ID: NCT00064402 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Start date: April 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD

NCT ID: NCT00063453 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Supplemental Selenium and Vitamin E and Pulmonary Function

Start date: August 2003
Phase: Phase 3
Study type: Interventional

To test whether supplementation with selenium and/or vitamin E affects pulmonary function.

NCT ID: NCT00062582 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

Start date: June 2003
Phase: Phase 3
Study type: Interventional

The aim of the study is to compare the effect of roflumilast and placebo on the lung function in patients with COPD.

NCT ID: NCT00059111 Completed - Hypertension Clinical Trials

Mechanisms Mediating Cardiovascular Disease in Children With Obstructive Sleep Apnea

Start date: April 2003
Phase: N/A
Study type: Observational

To identify the early effects of obstructive sleep apnea on the cardiovascular system of children.

NCT ID: NCT00056264 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD

Start date: December 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Obstructive Pulmonary Disease (COPD). Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

NCT ID: NCT00056147 Completed - Cystic Fibrosis Clinical Trials

Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of multiple dosages of INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis (CF) lung disease. Study drug will be administered through a nebulizer (a device that delivers medication as a mist by breathing it in).

NCT ID: NCT00052052 Completed - Pulmonary Fibrosis Clinical Trials

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Start date: September 2002
Phase: Phase 2
Study type: Interventional

Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for up to 48 weeks.